본문으로 이동

사업소개
BioSafety Level 3

연구실적

BL3 연구 및 사업 성과

특허

  • 사스 - 코로나바이러스2 중화항체 개발(한국출원:10-2022-0085495, 미국출원:PCT865-US)
  • 키메라 항원 수용체를 발현하는 면역 세포 및 트렙타비딘 스캐폴드 항체 유사 단백질을 포함하는 항암용 조성, 물 및 이의 용도(한국:10-2023-0161607)

논문

  • Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants, Virology journal, 2023-11 accepted
  • Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV. Sci Rep. 2023 May 20;13(1):8189.
  • Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants. Vaccine. 2023 Mar 10;41(11):1892-1901.
  • Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants. Vaccine. 2023 Mar 10;41(11):1892-1901.
  • Systemic delivery of CRISPR/Cas9 to hepatic tumors for cancer treatment using altered tropism of lentiviral vector, Biomaterials, Available online 1 April 2021, 120793 | https://doi.org/10.1016/j.biomaterials.2021.120793
  • Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection. Vaccine. 2020 Sep 3;38(39):6141-6152.
  • Effective inactivated influenza vaccine for the elderly using a single-stranded RNA-based adjuvant. Sci Rep. 2021 Jun 7;11(1):11981.
  • NanoformulatedSingle-Stranded RNA-Based Adjuvant with a Coordinative Amphiphile as an Effective Stabilizer: Inducing Humoral Immune Response by Activation of Antigen-Presenting Cells. AngewChem Int Ed Engl. 2020 Jul 6;59(28): 11540-11549.